ReviewAllergy2021
Advances and highlights in biomarkers of allergic diseases.
Review in Allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
122 citing papers in PubMed, 6 syntheses or guidelines pooled it, 207 citations in OpenAlex.
- The impact of Mediterranean diet adherence on allergic diseases: a systematic review and meta-analysis.Journal of nutritional science · 2026Pooled it
- Effects of vitamin D levels and vitamin D supplementation on allergic diseases: an umbrella review.Frontiers in allergy · 2026Pooled it
- Correlation between allergy and cancer: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Quercetin exhibits multi-target anti-allergic effects in animal models: a systematic review and meta-analysis of preclinical studies.Frontiers in pharmacology · 2025Pooled it
- Probiotics and the Potential of Genetic Modification as a Possible Treatment for Food Allergy.Nutrients · 2023Pooled it
- The Effect of Dietary Components of the Mediterranean Diet on Food Allergies: A Systematic Review.Nutrients · 2023Pooled it
- Proteomic Identification of Plasma Biomarkers of Response to IL-5 Inhibitor Biologics in Healthy Subjects.Clinical and translational science · 2025Trial
- Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.Nature medicine · 2025Trial
- Bioassays in Allergy: Technical Characteristics, Limitations, and Pathways to Clinical Implementation-An EAACI Position Paper.Clinical and translational allergy · 2026Review
- Opioid Misuse and Asthma and Allergic Diseases in College Students: The Role of Race and Ethnicity.AJPM focus · 2026Article
- Review
- Asthmatic symptoms in schoolchildren: effect of PMPediatric research · 2026Article
- Early Risk Assessment and Recognition of Allergies in Children: Rationale, Methodology, and Proposed Algorithms.Allergy · 2026Review
- A Case for Anti-IgE Vaccination.Allergy · 2026Review
- Bridging Rare to Common Diseases: Precision Medicine and the Transforming Landscape of Pediatric Allergy and Immunology.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Review
- Obesity, Air Pollution, and Epigenetic Modifications as Risk Factors for Asthma Phenotypes.International journal of molecular sciences · 2026Review
- Comparison of baseline TEWL values in OFC positive and negative patients.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Article
- Article
- Enhanced Early Detection of Allergic Rhinitis: A Prospective Study on a Symptom-Based Predictive Model.World journal of otorhinolaryngology - head and neck surgery · 2026Article
- Th17/Treg cell imbalance in allergic rhinitis: mechanisms and therapeutic implications.Genes and immunity · 2026Review
62 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the past years, there has been a global outbreak of allergic diseases, presenting a considerable medical and socioeconomical burden. A large fraction of allergic diseases is characterized by a type 2 immune response involving Th2 cells, type 2 innate lymphoid cells, eosinophils, mast cells, and M2 macrophages. Biomarkers are valuable parameters for precision medicine as they provide information on the disease endotypes, clusters, precision diagnoses, identification of therapeutic targets, and monitoring of treatment efficacies. The availability of powerful omics technologies, together with integrated data analysis and network-based approaches can help the identification of clinically useful biomarkers. These biomarkers need to be accurately quantified using robust and reproducible methods, such as reliable and point-of-care systems. Ideally, samples should be collected using quick, cost-efficient and noninvasive methods. In recent years, a plethora of research has been directed toward finding novel biomarkers of allergic diseases. Promising biomarkers of type 2 allergic diseases include sputum eosinophils, serum periostin and exhaled nitric oxide. Several other biomarkers, such as pro-inflammatory mediators, miRNAs, eicosanoid molecules, epithelial barrier integrity, and microbiota changes are useful for diagnosis and monitoring of allergic diseases and can be quantified in serum, body fluids and exhaled air. Herein, we review recent studies on biomarkers for the diagnosis and treatment of asthma, chronic urticaria, atopic dermatitis, allergic rhinitis, chronic rhinosinusitis, food allergies, anaphylaxis, drug hypersensitivity and allergen immunotherapy. In addition, we discuss COVID-19 and allergic diseases within the perspective of biomarkers and recommendations on the management of allergic and asthmatic patients during the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.